Promegestone: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
(Created page with "{{Drugbox | IUPAC_name = (8S,13S,14S,17S)-13,17-dimethyl-17-propionyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one | image =...")
 
No edit summary
Line 36: Line 36:
In addition to its [[progestogen]]ic properties, promegestone has also been found to act as a [[Receptor antagonist#Non-competitive|non-competitive antagonist]] of the [[nicotinic acetylcholine receptor]].<ref name="pmid9927618">{{cite journal | author = Blanton MP, Xie Y, Dangott LJ, Cohen JB | title = The steroid promegestone is a noncompetitive antagonist of the Torpedo nicotinic acetylcholine receptor that interacts with the lipid-protein interface | journal = Mol. Pharmacol. | volume = 55 | issue = 2 | pages = 269–78 |date=February 1999  | pmid = 9927618 | doi = | url = http://molpharm.aspetjournals.org/cgi/pmidlookup?view=long&pmid=9927618}}</ref>
In addition to its [[progestogen]]ic properties, promegestone has also been found to act as a [[Receptor antagonist#Non-competitive|non-competitive antagonist]] of the [[nicotinic acetylcholine receptor]].<ref name="pmid9927618">{{cite journal | author = Blanton MP, Xie Y, Dangott LJ, Cohen JB | title = The steroid promegestone is a noncompetitive antagonist of the Torpedo nicotinic acetylcholine receptor that interacts with the lipid-protein interface | journal = Mol. Pharmacol. | volume = 55 | issue = 2 | pages = 269–78 |date=February 1999  | pmid = 9927618 | doi = | url = http://molpharm.aspetjournals.org/cgi/pmidlookup?view=long&pmid=9927618}}</ref>


==See also==
 
* [[Demegestone]]
* [[Trimegestone]]
* [[Trimegestone]]


Line 44: Line 43:




{{Progestogens}}
{{Progestogenics}}
{{Cholinergics}}


[[Category:Drug]]
[[Category:Nicotinic antagonists]]
[[Category:Nicotinic antagonists]]
[[Category:Progestogens]]
[[Category:Steroids]]
[[Category:Steroids]]
{{genito-urinary-drug-stub}}
{{steroid-stub}}

Revision as of 19:56, 7 April 2015

Promegestone
Clinical data
SynonymsR-5020; RU-5020
ATC code
Identifiers
CAS Number
PubChem CID
ChemSpider
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC22H30O2
Molar mass326.472 g/mol
3D model (JSmol)

Promegestone (INN) (brand name Surgestone), also known as 17α,21-dimethyl-19-nor-Δ4,9-pregnadiene-3,20-dione, is a 19-norprogesterone derivative and steroidal progestin which was introduced in 1983 and is marketed in France, Portugal, and Argentina.[1][2][3][4] Indications include gynaecological conditions caused by luteal insufficiency, including premenopausal disorders, dysmenorrhea, and premenstrual syndrome.[4] Unlike some other progestins, promegestone is devoid of androgenic properties.[4]

In addition to its progestogenic properties, promegestone has also been found to act as a non-competitive antagonist of the nicotinic acetylcholine receptor.[5]


References

  1. ↑ R.A. Hill; H.L.J. Makin; D.N. Kirk (23 May 1991). Dictionary of Steroids. CRC Press. pp. 759–. ISBN 978-0-412-27060-4. Unknown parameter |coauthors= ignored (help)
  2. ↑ William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia, 3rd Edition. Elsevier. pp. 2935–. ISBN 978-0-8155-1856-3.
  3. ↑ Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 883–. ISBN 978-3-88763-075-1.
  4. ↑ 4.0 4.1 4.2 Cain (11 September 1984). ANNUAL REPORTS IN MED CHEMISTRY V19 PPR. Academic Press. pp. 323–. ISBN 978-0-08-058363-1.
  5. ↑ Blanton MP, Xie Y, Dangott LJ, Cohen JB (February 1999). "The steroid promegestone is a noncompetitive antagonist of the Torpedo nicotinic acetylcholine receptor that interacts with the lipid-protein interface". Mol. Pharmacol. 55 (2): 269–78. PMID 9927618.
Retrieved from "https://www.wikidoc.org/index.php?title=Promegestone&oldid=1084409"